Sarah Kathryn Rouan

This profile gathers the share dealings of Sarah Kathryn Rouan across 2 companies, led by Viking Therapeutics, Inc. and Navidea Biopharmaceuticals, Inc. Between 2 January 2019 and 2 January 2026, the trades on record add up to 15 filings.

On the open market, the record shows 3 purchases worth €60k and 3 sales worth €2.1M. The net balance comes to €2.0M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 6 share grants and 3 option exercises.

In size, the median ticket on the buying side is €28k.

The latest filing, published on 5 January 2026, reports a share grant in Viking Therapeutics, Inc. The last purchase on record was published on 8 April 2025, which is 564 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.